country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-112450

Copy Link Print Information

Olomoucine II

Name: Olomoucine II
Brand: MedChemExpress
SKU: HY-112450
Price: 120.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

Olomoucine II is a potent CDK inhibitor with IC₅₀ values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 500735-47-7
Formel: C₁₉H₂₆N₆O₂
Molecular Weight:370.45

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Olomoucine II Chemical Structure

CAS. Nr.: 500735-47-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

CDK9/cycT

0.06 μM (IC₅₀)

CDK2/cyclinE

0.1 μM (IC₅₀)

CDK7/cyclin H

0.45 μM (IC₅₀)

Cdk1/cyclin B

7.6 μM (IC₅₀)

CDK4/cyclinD1

19.8 μM (IC₅₀)

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BJ	EC₅₀	5.4 μM Compound: olomoucine II	Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human BJ cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
CCRF-CEM	EC₅₀	8.1 μM Compound: olomoucine II	Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human CEM cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
CCRF-CEM	IC₅₀	3 μM Compound: Olomoucine II	In vitro cytotoxic effect on CEM cancer cell line In vitro cytotoxic effect on CEM cancer cell line	[PMID: 12392733]
CCRF-CEM	IC₅₀	7.4 μM Compound: Olomoucine II	Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
G-361	IC₅₀	6.3 μM Compound: Olomoucine II	In vitro cytotoxic effect on G361 cancer cell line In vitro cytotoxic effect on G361 cancer cell line	[PMID: 12392733]
G-361	IC₅₀	9.2 μM Compound: Olomoucine II	Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HCT-116	IC₅₀	4.1 μM Compound: Olomoucine II	Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HeLa	EC₅₀	9.9 μM Compound: olomoucine II	Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human HeLa cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
HOS	IC₅₀	10.6 μM Compound: Olomoucine II	Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HOS	IC₅₀	6.3 μM Compound: Olomoucine II	In vitro cytotoxic effect on HOS cancer cell line In vitro cytotoxic effect on HOS cancer cell line	[PMID: 12392733]
K562	IC₅₀	11.1 μM Compound: Olomoucine II	In vitro cytotoxic effect on K562 cancer cell line In vitro cytotoxic effect on K562 cancer cell line	[PMID: 12392733]
K562	IC₅₀	23 μM Compound: Olomoucine II	Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
MCF7	EC₅₀	4.6 μM Compound: olomoucine II	Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human MCF7 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
MCF7	IC₅₀	5.3 μM Compound: Olomoucine II	In vitro cytotoxic effect on MCF-7 cancer cell line In vitro cytotoxic effect on MCF-7 cancer cell line	[PMID: 12392733]
MCF7	IC₅₀	9.1 μM Compound: Olomoucine II	Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
RPMI-8226	EC₅₀	6 μM Compound: olomoucine II	Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human RPMI8226 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]
Sf9	IC₅₀	50 nM Compound: Olomoucine II	Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate	[PMID: 22770608]
U-266	EC₅₀	7.2 μM Compound: olomoucine II	Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay Cytotoxicity against human U266 cells assessed as viable cells after 72 hrs by calcein AM assay	[PMID: 20192247]

In Vitro

Olomoucine II (72 h) shows antiproliferative activity with IC₅₀s of 9.3, 9.2, 10.5, 13.6, 5.0, 10.8, 5.3, 2.7, 16.3 µM for HOS, T98G, HBL100, BT474, MCF-7, HT-29, CCRF-CEM, BV173, HL60 cells, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

HOS, T98G, HBL100, BT474, MCF-7, HT-29, CCRF-CEM, BV173, HL60 cells
Concentration:
Incubation Time:

72 h
Result:

Showed antiproliferative activity with IC₅₀s of 9.3, 9.2, 10.5, 13.6, 5.0, 10.8, 5.3, 2.7, 16.3 µM for HOS, T98G, HBL100, BT474, MCF-7, HT-29, CCRF-CEM, BV173, HL60 cells, respectively.

Chemical Information

CAS. Nr. 500735-47-7
Appearance Solid
Molecular Weight 370.45
Formel C₁₉H₂₆N₆O₂
Color White to off-white
SMILES

OC1=CC=CC=C1CNC2=C3N=CN(C(C)C)C3=NC(N[C@@H](CO)CC)=N2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Krystof V, et al. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci. 2005 Aug;62(15):1763-71. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Olomoucine II

FIT-039

FIT-039 (Standard)

Nimbolide

Yatein

CDK9-IN-1

PGP-4008

Navitoclax-d8

Nylidrin

Nimbolide (Standard)

CDK9-IN-1 (Standard)

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Bioz

Olomoucine II

FIT-039

FIT-039 (Standard)

Nimbolide

Yatein

CDK9-IN-1

PGP-4008

Navitoclax-d8

Nylidrin

Nimbolide (Standard)

CDK9-IN-1 (Standard)

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Olomoucine II Related Classifications

HY-112450 Related Classifications

Bioz